TRINITÀ
Innovative Therapies and Radiopharmaceutical agents for highly aggressive oncological diseases
Scheda del progetto
The TRINITÀ project aims to develop a new therapeutic and diagnostic agents for the treatment of oncological pathologies with a high need of cures. The collaboration between the two partner Dompé Farmaceutici and ViroStatics, supported by the scientific experience of University of Pavia, will focus on the synthesis, preclinical characterization, and afvancement of the development of innovative drugs, the development of new personalized drug delivery systems, and advanced diagnostic probes using state-of-art digital technologies. The relevant oncological pathologies of interest in the project include ductal adenocarcinoma, lung cancer, malignant pleural mesothelioma and breast cancer resistant to CDK4/6 inhibitors.
Contact:
Samuele Lillini
The project aims to characterize proprietary molecules for oncological treatments, with a focus on potential use in new radiopharmaceuticals for diagnosis or treatment. The selected molecules are Ladarixin, DF2755A and DFL23806, characterized by a paramagnetic 19F heteronucleus. The innovative approach involves the use of Magnetic Resonance Imaging (MRI) techniques and radio imaging thorugh microPET, with the goal of developing diagnostic radiopharmaceuticals. This project will contribute to personalized medicine and scientific advancement.
The project aims for pharmaceutical innovation, with the objective of providing personalized and regenerative therapeutic solutions. The success of the project will not only expand scientific and technological knowledge but will also generate new job opportunities for researchers and technicians in the field, paving the way for further research and development programs in oncology based on the knowledge generated by TRINITÀ project.
The project will have a positive scientific impact by providing the medical community and patients with new therapeutic agents for the treatment of oncological pathologies that currently lack effective treatments, such as highly aggressive tumors. This will benefit the scientific and clinical community, improving the quality of life of patients and reducing hospital costs.